Premium
Cabergoline scavenges peroxynitrite enhanced by l ‐DOPA therapy in patients with Parkinson's disease
Author(s) -
Isobe C.,
Abe T.,
Kikuchi T.,
Murata T.,
Sato C.,
Terayama Y.
Publication year - 2006
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2006.01207.x
Subject(s) - cabergoline , medicine , dopaminergic , peroxynitrite , parkinson's disease , nitrotyrosine , oxidative stress , dopamine , cerebrospinal fluid , disease , pharmacology , gastroenterology , biochemistry , chemistry , nitric oxide , nitric oxide synthase , hormone , prolactin , enzyme , superoxide
Long‐term or high‐dose l ‐DOPA therapy in patients with Parkinson's disease (PD) may accelerate degeneration of dopaminergic neurons, possibly by increasing oxidative stress. To investigate the effects of cabergoline on peroxynitrite‐mediated oxidative damage caused by l ‐DOPA, the concentration of 3‐nitrotyrosine in cerebrospinal fluid (CSF) of 18 PD patients was compared with that in 20 normal controls. The concentration of 3‐nitrotyrosine in patients following l ‐DOPA therapy was significantly higher than in untreated PD patients and controls. On the other hand, the concentration in PD patients after cabergoline therapy was significantly lower than in PD patients after l ‐DOPA therapy alone. These data suggest that cabergoline scavenges peroxynitrite induced by l ‐DOPA in patients with PD.